TTX-RIGA / TransCode - LARVOL DELTA

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy. (PubMed, Mol Imaging Biol) - "Our template-driven approach brings RIG-I closer to becoming a clinically relevant target in oncology by specifically activating immune responses within tumor cells through systemic RIG-I agonist delivery."

Journal • Melanoma • Oncology • Solid Tumor • MIR21

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA (GlobeNewswire) - "TransCode Therapeutics... reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA. The study showed a significant inhibition of tumor growth....In a mouse model of melanoma, systemic injection of TTX-RIGA demonstrated that the therapeutic candidate was effective in reducing primary tumor growth. Remarkably, it also elicited an immune response against secondary recurrent tumors, inhibiting their growth by 70%."

Preclinical • Melanoma

TransCode Therapeutics Reports 2022 Results; Provides Business Update (GlobeNewswire) - "TransCode’s goals to continue to advance its portfolio include: TTX-MC138: (i) Obtain institutional review board approval of our FIH Phase 0 clinical study at the center where we plan to conduct the trial in up to 12 cancer patients with advanced solid tumors; (ii) Report topline data readout from the Phase 0 trial; (iii) Publish preclinical results supporting TTX-MC138 in pancreatic cancer and TTX-RIGA in melanoma....(iv) Publish preclinical results supporting TTX-MC138 in glioblastoma; (v) Complete IND-enabling studies to support filing an IND application for a Phase I/2 clinical trial of TTX-MC138."

Clinical data • Preclinical • Trial status • Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Glioblastoma • Glioma • Melanoma • Oncology • Pancreatic Cancer • Skin Cancer • Solid Tumor

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma (GlobeNewswire) - "TransCode Therapeutics...reported successful preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma....In preclinical studies, TransCode’s delivery of TTX-RIGA inside tumors and metastases generated an RNA-based agonist of the RIG-I gene, targeting activation of innate immunity in the tumor microenvironment in multiple solid tumors, holding promise for the development of a novel class of immunotherapeutics for cancer treatment."

Preclinical • Melanoma • Oncology • Solid Tumor

TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update (GlobeNewswire) - "Planned Milestones...Publication of preclinical results supporting therapeutic candidate, TTX-RIGA; Continuation of preclinical studies for therapeutic candidates TTX-RIGA, TTX-siPDL1, and TTX-siLIN28B....Research and development expense was $1.9 million in the first quarter of 2022, compared to $0.3 million in the first quarter of 2021."

Commercial • Preclinical • Oncology